Dr Reddys Launches Generic Fulvestrant Injection In Us
Pharma Major Dr Reddy'S Laboratories On Monday Said It Has Launched Generic Fulvestrant Injection, Used For The Treatment Of Advanced Breast Cancer, In The Us Market. The Company Has Launched Fulvestrant Injection, 250 Mg/5 Ml (50 Mg/Ml) Per Single-Dose Syringe, Approved By The United States Food And Drug Administration (Usfda), Dr Reddy'S Laboratories Said In A Filing To Bse.The Product Is A Generic Version Of Faslodex Injection In The Same Strength, It Added.According To The Iqvia Health Data, Faslodex Brand And Generic Market Had Us Sales Of Around Usd 407 Million Mat For 12 Months To June 2020, The Filing Said.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
